- Report
- January 2024
- 175 Pages
Global
From €4766EUR$5,000USD£4,023GBP
- Report
- July 2024
- 188 Pages
Global
From €5338EUR$5,600USD£4,506GBP
- Report
- May 2024
- 131 Pages
Global
From €6195EUR$6,499USD£5,229GBP
- Report
- May 2024
- 137 Pages
Global
From €6195EUR$6,499USD£5,229GBP
- Report
- May 2024
- 135 Pages
Global
From €6195EUR$6,499USD£5,229GBP
- Report
- April 2024
- 180 Pages
Global
From €4671EUR$4,900USD£3,942GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4718EUR$4,950USD£3,983GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4718EUR$4,950USD£3,983GBP
- Report
- April 2024
- 100 Pages
Global
From €3808EUR$3,995USD£3,214GBP
- Report
- June 2024
- 76 Pages
Global
From €1334EUR$1,400USD£1,126GBP
- Report
- March 2024
- 102 Pages
Global
From €1620EUR$1,700USD£1,368GBP
- Report
- March 2024
- 191 Pages
Global
From €3755EUR$3,939USD£3,169GBP
- Report
- July 2023
- 147 Pages
Global
From €2145EUR$2,250USD£1,810GBP
- Report
- June 2024
- 184 Pages
Global
From €3755EUR$3,939USD£3,169GBP
- Report
- November 2023
- 150 Pages
Global
From €4623EUR$4,850USD£3,902GBP
- Report
- August 2023
- 120 Pages
Global
From €5671EUR$5,950USD£4,787GBP
- Report
- July 2024
- 93 Pages
Global
From €5338EUR$5,600USD£4,506GBP
- Report
- July 2024
- 196 Pages
Global
From €5195EUR$5,450USD£4,385GBP
- Report
- January 2024
- 200 Pages
Global
From €4766EUR$5,000USD£4,023GBP
- Report
- July 2024
- 145 Pages
Global
From €3716EUR$3,899USD£3,137GBP
![Loading Indicator](//www.researchandmarkets.com/images/loading.gif)
Hemophilia is a rare, inherited bleeding disorder in which the blood does not clot properly. People with hemophilia lack certain proteins, called clotting factors, which are necessary for normal blood clotting. Without these clotting factors, even a minor injury can cause excessive bleeding. Hemophilia is classified into two main types, hemophilia A and hemophilia B, depending on the clotting factor that is missing.
The hemophilia market is a subset of the hematology market, which includes treatments for a variety of blood-related disorders. The hemophilia market is composed of treatments for hemophilia A and B, such as recombinant clotting factors, gene therapy, and other treatments. These treatments are used to reduce the frequency and severity of bleeding episodes, as well as to prevent bleeding in the first place.
Some companies in the hemophilia market include Novo Nordisk, Pfizer, Shire, Bayer, and CSL Behring. Show Less Read more